MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Short Interest Update

MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 393,000 shares, a growth of 260.2% from the March 31st total of 109,100 shares. Based on an average trading volume of 219,000 shares, the short-interest ratio is presently 1.8 days. Currently, 20.6% of the shares of the stock are short sold.

Institutional Investors Weigh In On MyMD Pharmaceuticals

A hedge fund recently raised its stake in MyMD Pharmaceuticals stock. Cambria Investment Management L.P. lifted its holdings in shares of MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) by 184.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 171,570 shares of the company’s stock after purchasing an additional 111,335 shares during the period. Cambria Investment Management L.P. owned 0.38% of MyMD Pharmaceuticals worth $102,000 as of its most recent filing with the SEC. 9.64% of the stock is owned by institutional investors and hedge funds.

MyMD Pharmaceuticals Price Performance

MYMD stock traded down $0.05 during midday trading on Thursday, reaching $2.81. 20,266 shares of the stock were exchanged, compared to its average volume of 188,870. The company has a fifty day moving average price of $2.83 and a 200 day moving average price of $6.32. MyMD Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $70.50. The stock has a market capitalization of $6.07 million, a PE ratio of -0.52 and a beta of 2.29.

About MyMD Pharmaceuticals

MyMD Pharmaceuticals, Inc, a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression.